Studies on anticancer activities of lactoferrin and lactoferricin

Current Protein and Peptide Science

Volumn 14, Issue 6, 2013, Pages 492-503

  Yin, Cui Ming ^a   Wong, Jack Ho ^a   Xia, Jiang ^a   Ng, Tzi Bun ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Application; Cancer; Delta lactoferrin; Drug delivery; Lactoferricin; Lactoferrin; Mechanism; Talactoferrin

Indexed keywords

ANTINEOPLASTIC AGENT; APOLACTOFERRIN B; CASPASE; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN E; DELTA LACTOFERRIN; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTOFERRICIN; LACTOFERRICIN B; LACTOFERRIN; LTX 302; MITOGEN ACTIVATED PROTEIN KINASE; POLYPHENOL; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P21; PROTEIN P27; PROTEIN P53; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TALACTOFERRIN; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; ANGIOGENESIS INHIBITOR;

AMINO ACID SEQUENCE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BODY FLUID; CELL CYCLE ARREST; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FIBROSARCOMA; HUMAN; IMMUNOMODULATION; LUNG NON SMALL CELL CANCER; LYMPHOMA; METAL BINDING; METASTASIS; METASTASIS INHIBITION; MOUTH CANCER; MOUTH SQUAMOUS CELL CARCINOMA; NECROSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; TUMOR VOLUME; ANIMAL; CELL CYCLE; CHEMISTRY; DRUG EFFECTS; IMMUNOLOGY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; HUMANS; LACTOFERRIN; NECROSIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84888261969     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/13892037113149990066     Document Type: Review

References (119)

1. Brock, J. H. The physiology of lactoferrin. Biochem. Cell. Biol., 2002, 80(1), 1-6.
2. Baker, H. M.; Anderson, B. F.; Baker, E. N. Dealing with iron: common structural principles in proteins that transport iron and heme. Proc. Natl. Acad. Sci. U S A, 2003, 100(7), 3579-3583.
3. Masson, P. L.; Heremans, J. F.; Dive, C. H. An iron-binding protein common to many external secretions. Clinica. Chimica. Acta., 1966, 14(6), 735-739.
4. Blanc, B.; Isliker, H.[Isolation and characterization of the red siderophilic protein from maternal milk: lactotransferrin] Bull. Soc. Chim. Biol. (Paris), 1961, 43, 929-943.
5. Tuccari, G.; Barresi, G. Lactoferrin in human tumours: immunohistochemical investigations during more than 25 years. Biometals, 2011, 24(5), 775-784.
6. Garcia-Montoya, I. A.; Cendon, T. S.; Arevalo-Gallegos, S.; Rascon-Cruz, Q. Lactoferrin a multiple bioactive protein: An overview. Biochim. Biophys. Acta., 2012, 1820(3), 226-236.
7. Bellamy, W.; Takase, M.; Wakabayashi, H.; Kawase, K.; Tomita, M. Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J. Appl. Bacteriol., 1992, 73(6), 472-479.
8. Gifford, J. L.; Hunter, H. N.; Vogel, H. J. Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell. Mol. Life Sci., 2005, 62(22), 2588-2598.
9. Yoo, Y. C.; Watanabe, S.; Watanabe, R.; Hata, K.; Shimazaki, K.; Azuma, I. Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn. J. Cancer Res., 1997, 88(2), 184-190.
10. Davidson, L. A.; Lonnerdal, B. Isolation and characterization of rhesus monkey milk lactoferrin. Pediatr. Res., 1986, 20(2), 197-201.
11. Khan, J. A.; Kumar, P.; Paramasivam, M.; Yadav, R. S.; Sahani, M. S.; Sharma, S.; Srinivasan, A.; Singh, T. P. Camel lactoferrin, a transferrin-cum-lactoferrin: crystal structure of camel apolactoferrin at 2.6 A resolution and structural basis of its dual role. J. Mol. Biol., 2001, 309(3), 751-761.
12. Kumar, S.; Bhatia, K. L. Characterization of buffalo lactotransferrin by polyacrylamide gel electrophoresis in 6 M urea. J. Chromatogr., 1988, 434(1), 228-231.
13. Masson, P. L.; Heremans, J. F. Lactoferrin in milk from different species. Comp. Biochem. Physiol. B., 1971, 39(1), 119-129.
14. Masson, P.; Heremans, J. F.; Prignot, J. Immunohistochemical localization of the iron-binding protein lactoferrin in human bronchial glands. Experientia, 1965, 21(10), 604-605.
15. Shimazaki, K.; Oota, K.; Nitta, K.; Ke, Y. Comparative study of the iron-binding strengths of equine, bovine and human lactoferrins. J. Dairy Res., 1994, 61(4), 563-566.
16. van der Strate, B. W.; Beljaars, L.; Molema, G.; Harmsen, M. C.; Meijer, D. K. Antiviral activities of lactoferrin. Antiviral Res., 2001, 52(3), 225-239.
17. Levay, P. F.; Viljoen, M. Lactoferrin: a general review. Haematologica, 1995, 80(3), 252-267.
18. Mason, D. Y.; Taylor, C. R. Distribution of transferrin, ferritin, and lactoferrin in human tissues. J. Clin. Pathol., 1978, 31(4), 316-327.
19. Ieni, A.; Barresi, V.; Grosso, M.; Rosa, M. A.; Tuccari, G. Lactoferrin immuno-expression in human normal and neoplastic bone tissue. J. Bone Miner. Metab., 2009, 27(3), 364-371.
20. Ieni, A.; Barresi, V.; Grosso, M.; Rosa, M. A.; Tuccari, G. Immunolocalization of lactoferrin in cartilage-forming neoplasms. J. Orthop. Sci., 2009, 14(6), 732-737.
21. Houghton, M. R.; Gracey, M.; Burke, V.; Bottrell, C.; Spargo, R. M. Breast milk lactoferrin levels in relation to maternal nutritional status. J. Pediatr. Gastroenterol. Nutr., 1985, 4(2), 230-233.
22. Masson, P. L.; Heremans, J. F. Lactoferrin in milk from different species. Comp. Biochem. Physiol. B., 1971, 39(1), 119-129.
23. Steijns, J. M.; van Hooijdonk, A. C. Occurrence, structure, biochemical properties and technological characteristics of lactoferrin. Br. J. Nutr., 2000, 84 Suppl 1, S11-S17.
24. Furmanski, P.; Li, Z. P.; Fortuna, M. B.; Swamy, C. V.; Das, M. R. Multiple molecular forms of human lactoferrin. Identification of a class of lactoferrins that possess ribonuclease activity and lack iron-binding capacity. J. Exp. Med., 1989, 170(2), 415-429.
25. Anderson, B. F.; Baker, H. M.; Norris, G. E.; Rice, D. W.; Baker, E. N. Structure of human lactoferrin: crystallographic structure analysis and refinement at 2.8 A resolution. J. Mol. Biol., 1989, 209(4), 711-734.
26. Anderson, B. F.; Baker, H. M.; Dodson, E. J.; Norris, G. E.; Rumball, S. V.; Waters, J. M.; Baker, E. N. Structure of human lactoferrin at 3.2-A resolution. Proc. Natl. Acad. Sci. U S A, 1987, 84(7), 1769-1773.
27. Moore, S. A.; Anderson, B. F.; Groom, C. R.; Haridas, M.; Baker, E. N. Three-dimensional structure of diferric bovine lactoferrin at 2.8 A resolution. J. Mol. Biol., 1997, 274(2), 222-236.
28. Baker, H. M.; Anderson, B. F.; Baker, E. N. Dealing with iron: common structural principles in proteins that transport iron and heme. Proc. Natl. Acad. Sci. U S A, 2003, 100(7), 3579-3583.
29. Wally, J.; Buchanan, S. K. A structural comparison of human serum transferrin and human lactoferrin. Biometals, 2007, 20(3-4), 249-262.
30. Moguilevsky, N.; Retegui, L. A.; Masson, P. L. Comparison of human lactoferrins from milk and neutrophilic leucocytes. Relative molecular mass, isoelectric point, iron-binding properties and uptake by the liver. Biochem. J., 1985, 229(2), 353-359.
31. Kuwata, H.; Yip, T. T.; Tomita, M.; Hutchens, T. W. Direct evidence of the generation in human stomach of an antimicrobial peptide domain (lactoferricin) from ingested lactoferrin. Biochim. Biophys. Acta, 1998, 1429(1), 129-141.
32. Furlund, C. B.; Ulleberg, E. K.; Devold, T. G.; Flengsrud, R.; Jacobsen, M.; Sekse, C.; Holm, H.; Vegarud, G. E. Identification of lactoferrin peptides generated by digestion with human gastrointestinal enzymes. J. Dairy Sci., 2013, 96(1), 75-88.
33. Vorland, L. H.; Ulvatne, H.; Andersen, J.; Haukland, H.; Rekdal, O.; Svendsen, J. S.; Gutteberg, T. J. Lactoferricin of bovine origin is more active than lactoferricins of human, murine and caprine origin. Scand. J. Infect. Dis., 1998, 30(5), 513-517.
34. Chen, H. L.; Yen, C. C.; Lu, C. Y.; Yu, C. H.; Chen, C. M. Synthetic porcine lactoferricin with a 20-residue peptide exhibits antimicrobial activity against Escherichia coli, Staphylococcus aureus, and Candida albicans. J. Agric. Food Chem., 2006, 54(9), 3277-3282.
35. Strom, M. B.; Rekdal, O.; Stensen, W.; Svendsen, J. S. Increased antibacterial activity of 15-residue murine lactoferricin derivatives. J. Pept. Res., 2001, 57(2), 127-139.
36. Vorland, L. H.; Ulvatne, H.; Andersen, J.; Haukland, H.; Rekdal, O.; Svendsen, J. S.; Gutteberg, T. J. Lactoferricin of bovine origin is more active than lactoferricins of human, murine and caprine origin. Scand. J. Infect. Dis., 1998, 30(5), 513-517.
37. Hunter, H. N.; Demcoe, A. R.; Jenssen, H.; Gutteberg, T. J.; Vogel, H. J. Human lactoferricin is partially folded in aqueous solution and is better stabilized in a membrane mimetic solvent. Antimicrob. Agents Chemother., 2005, 49(8), 3387-3395.
38. Dionysius, D. A.; Milne, J. M. Antibacterial peptides of bovine lactoferrin: purification and characterization. J. Dairy Sci., 1997, 80(4), 667-674.
39. Rey, M. W.; Woloshuk, S. L.; DeBoer, H. A.; Pieper, F. R. Complete nucleotide sequence of human mammary gland lactoferrin. Nucleic Acids Res., 1990, 18(17), 5288.
40. Pierce, A.; Colavizza, D.; Benaissa, M.; Maes, P.; Tartar, A.; Montreuil, J.; Spik, G. Molecular cloning and sequence analysis of bovine lactotransferrin. Eur. J. Biochem., 1991, 196(1), 177-184.
41. Hwang, P. M.; Zhou, N.; Shan, X.; Arrowsmith, C. H.; Vogel, H. J. Three-dimensional solution structure of lactoferricin B, an antimicrobial peptide derived from bovine lactoferrin. Biochemistry, 1998, 37(12), 4288-4298.
42. Hunter, H. N.; Demcoe, A. R.; Jenssen, H.; Gutteberg, T. J.; Vogel, H. J. Human lactoferricin is partially folded in aqueous solution and is better stabilized in a membrane mimetic solvent. Antimicrob., Agents Chemother., 2005, 49(8), 3387-3395.
43. Bellamy, W.; Takase, M.; Yamauchi, K.; Wakabayashi, H.; Kawase, K.; Tomita, M. Identification of the bactericidal domain of lactoferrin. Biochim. Biophys. Acta, 1992, 1121(1-2), 130-136.
44. Jenssen, H.; Andersen, J. H.; Uhlin-Hansen, L.; Gutteberg, T. J.; Rekdal, O. Anti-HSV activity of lactoferricin analogues is only partly related to their affinity for heparan sulfate. Antiviral Res., 2004, 61(2), 101-109.
45. Hunter, H. N.; Demcoe, A. R.; Jenssen, H.; Gutteberg, T. J.; Vogel, H. J. Human lactoferricin is partially folded in aqueous solution and is better stabilized in a membrane mimetic solvent. Antimicrob. Agents Chemother., 2005, 49(8), 3387-3395.
46. Cappelli, G.; Paladini, S.; D'Agata, A. Tumor markers in the diagnosis of pancreatic cancer. Tumori, 1999, 85(1 Suppl 1), S19-S21.
47. Miyagi, T.; Wada, T.; Yamaguchi, K.; Hata, K. Sialidase and malignancy: a minireview. Glycoconj. J., 2004, 20(3), 189-198.
48. Utsugi, T.; Schroit, A. J.; Connor, J.; Bucana, C. D.; Fidler, I. J. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res., 1991, 51(11), 3062-3066.
49. Williamson, P.; Schlegel, R. A. Back and forth: the regulation and function of transbilayer phospholipid movement in eukaryotic cells. Mol. Membr. Biol., 1994, 11(4), 199-216.
50. Zwaal, R. F.; Schroit, A. J. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood, 1997, 89(4), 1121-1132.
51. McKeown, S. T.; Lundy, F. T.; Nelson, J.; Lockhart, D.; Irwin, C. R.; Cowan, C. G.; Marley, J. J. The cytotoxic effects of human neutrophil peptide-1 (HNP1) and lactoferrin on oral squamous cell carcinoma (OSCC) in vitro. Oral Oncol., 2006, 42(7), 685-690.
52. Brandenburg, K.; Jurgens, G.; Muller, M.; Fukuoka, S.; Koch, M. H. Biophysical characterization of lipopolysaccharide and lipid A inactivation by lactoferrin. Biol. Chem., 2001, 382(8), 1215-1225.
53. Appelmelk, B. J.; An, Y. Q.; Geerts, M.; Thijs, B. G.; de Boer, H. A.; MacLaren, D. M.; de Graaff, J.; Nuijens, J. H. Lactoferrin is a lipid A-binding protein. Infect. Immun., 1994, 62(6), 2628-2632.
54. Mann, D. M.; Romm, E.; Migliorini, M. Delineation of the glycosaminoglycan-binding site in the human inflammatory response protein lactoferrin. J. Biol. Chem., 1994, 269(38), 23661-23667.
55. Damiens, E.; El, Y. I.; Mazurier, J.; Elass-Rochard, E.; Duthille, I.; Spik, G.; Boilly-Marer, Y. Role of heparan sulphate proteoglycans in the regulation of human lactoferrin binding and activity in the MDA-MB-231 breast cancer cell line. Eur. J. Cell. Biol., 1998, 77(4), 344-351.
56. Mader, J. S.; Smyth, D.; Marshall, J.; Hoskin, D. W. Bovine lactoferricin inhibits basic fibroblast growth factor-and vascular endothelial growth factor165-induced angiogenesis by competing for heparin-like binding sites on endothelial cells. Am. J. Pathol., 2006, 169(5), 1753-1766.
57. Hirotani, Y.; Ikeda, K.; Kato, R.; Myotoku, M.; Umeda, T.; Ijiri, Y.; Tanaka, K. Protective effects of lactoferrin against intestinal mucosal damage induced by lipopolysaccharide in human intestinal Caco-2 cells. Yakugaku Zasshi, 2008, 128(9), 1363-1368.
58. Puddu, P.; Latorre, D.; Valenti, P.; Gessani, S. Immunoregulatory role of lactoferrin-lipopolysaccharide interactions. Biometals, 2010, 23(3), 387-397.
59. Drago-Serrano, M. E.; de la Garza-Amaya, M.; Luna, J. S.; Campos-Rodriguez, R. Lactoferrin-lipopolysaccharide (LPS) binding as key to antibacterial and antiendotoxic effects. Int. Immunopharmacol., 2012, 12(1), 1-9.
60. Suzuki, Y. A.; Lopez, V.; Lonnerdal, B. Mammalian lactoferrin receptors: structure and function. Cell. Mol. Life Sci., 2005, 62(22), 2560-2575.
61. Ashida, K.; Sasaki, H.; Suzuki, Y. A.; Lonnerdal, B. Cellular internalization of lactoferrin in intestinal epithelial cells. Biometals, 2004, 17(3), 311-315.
62. Oh, S. M.; Pyo, C. W.; Kim, Y.; Choi, S. Y. Neutrophil lactoferrin upregulates the human p53 gene through induction of NF-kappaB activation cascade. Oncogene, 2004, 23(50), 8282-8291.
63. Mader, J. S.; Salsman, J.; Conrad, D. M.; Hoskin, D. W. Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines. Mol. Cancer Ther., 2005, 4(4), 612-624.
64. Andersen, J. H.; Jenssen, H.; Sandvik, K.; Gutteberg, T. J. Anti-HSV activity of lactoferrin and lactoferricin is dependent on the presence of heparan sulphate at the cell surface. J. Med. Virol., 2004, 74(2), 262-271.
65. Eliassen, L. T.; Berge, G.; Leknessund, A.; Wikman, M.; Lindin, I.; Lokke, C.; Ponthan, F.; Johnsen, J. I.; Sveinbjornsson, B.; Kogner, P.; Flaegstad, T.; Rekdal, O. The antimicrobial peptide, lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo. Int. J. Cancer, 2006, 119(3), 493-500.
66. Yoo, Y. C.; Watanabe, R.; Koike, Y.; Mitobe, M.; Shimazaki, K.; Watanabe, S.; Azuma, I. Apoptosis in human leukemic cells induced by lactoferricin, a bovine milk protein-derived peptide: involvement of reactive oxygen species. Biochem. Biophys. Res. Commun., 1997, 237(3), 624-628.
67. de Mejia, E. G.; Dia, V. P. The role of nutraceutical proteins and peptides in apoptosis, angiogenesis, and metastasis of cancer cells. Cancer Metastasis Rev., 2010, 29(3), 511-528.
68. Damiens, E.; El, Y. I.; Mazurier, J.; Duthille, I.; Spik, G.; Boilly-Marer, Y. Lactoferrin inhibits G1 cyclin-dependent kinases during growth arrest of human breast carcinoma cells. J. Cell Biochem., 1999, 74(3), 486-498.
69. Xiao, Y.; Monitto, C. L.; Minhas, K. M.; Sidransky, D. Lactoferrin down-regulates G1 cyclin-dependent kinases during growth arrest of head and neck cancer cells. Clin. Cancer Res., 2004, 10(24), 8683-8686.
70. Zhou, Y.; Zeng, Z.; Zhang, W.; Xiong, W.; Wu, M.; Tan, Y.; Yi, W.; Xiao, L.; Li, X.; Huang, C.; Cao, L.; Tang, K.; Li, X.; Shen, S.; Li, G. Lactotransferrin: a candidate tumor suppressor-Deficient expression in human nasopharyngeal carcinoma and inhibition of NPC cell proliferation by modulating the mitogen-activated protein kinase pathway. Int. J. Cancer, 2008, 123(9), 2065-2072.
71. Freiburghaus, C.; Janicke, B.; Lindmark-Mansson, H.; Oredsson, S. M.; Paulsson, M. A. Lactoferricin treatment decreases the rate of cell proliferation of a human colon cancer cell line. J. Dairy Sci., 2009, 92(6), 2477-2484.
72. West, N. J.; Courtney, E. D.; Poullis, A. P.; Leicester, R. J. Apoptosis in the colonic crypt, colorectal adenomata, and manipulation by chemoprevention. Cancer Epidemiol. Biomarkers Prev., 2009, 18(6), 1680-1687.
73. Wyllie, A. H.; Beattie, G. J.; Hargreaves, A. D. Chromatin changes in apoptosis. Histochem. J., 1981, 13(4), 681-692.
74. Colitti, M. BCL-2 family of proteins and mammary cellular fate. Anat. Histol. Embryol., 2012, 41(4), 237-247.
75. Lee, S. H.; Park, S. W.; Pyo, C. W.; Yoo, N. K.; Kim, J.; Choi, S. Y. Requirement of the JNK-associated Bcl-2 pathway for human lactoferrin-induced apoptosis in the Jurkat leukemia T cell line. Biochimie, 2009, 91(1), 102-108.
76. Lee, S. H.; Hwang, H. M.; Pyo, C. W.; Hahm, D. H.; Choi, S. Y. E2F1-directed activation of Bcl-2 is correlated with lactoferrininduced apoptosis in Jurkat leukemia T lymphocytes. Biometals, 2010, 23(3), 507-514.
77. Furlong, S. J.; Mader, J. S.; Hoskin, D. W. Bovine lactoferricin induces caspase-independent apoptosis in human B-lymphoma cells and extends the survival of immune-deficient mice bearing Blymphoma xenografts. Exp. Mol. Pathol., 2010, 88(3), 371-375.
78. Furlong, S. J.; Ridgway, N. D.; Hoskin, D. W. Modulation of ceramide metabolism in T-leukemia cell lines potentiates apoptosis induced by the cationic antimicrobial peptide bovine lactoferricin. Int. J. Oncol., 2008, 32(3), 537-544.
79. Norrby, K.; Mattsby-Baltzer, I.; Innocenti, M.; Tuneberg, S. Orally administered bovine lactoferrin systemically inhibits VEGF(165)-mediated angiogenesis in the rat. Int. J. Cancer, 2001, 91(2), 236-240.
80. Shimamura, M.; Yamamoto, Y.; Ashino, H.; Oikawa, T.; Hazato, T.; Tsuda, H.; Iigo, M. Bovine lactoferrin inhibits tumor-induced angiogenesis. Int. J. Cancer, 2004, 111(1), 111-116.
81. Kozu, T.; Iinuma, G.; Ohashi, Y.; Saito, Y.; Akasu, T.; Saito, D.; Alexander, D. B.; Iigo, M.; Kakizoe, T.; Tsuda, H. Effect of orally administered bovine lactoferrin on the growth of adenomatous colorectal polyps in a randomized, placebo-controlled clinical trial. Cancer Prev. Res. (Phila), 2009, 2(11), 975-983.
82. Norrby, K. Human apo-lactoferrin enhances angiogenesis mediated by vascular endothelial growth factor A in vivo. J. Vasc. Res., 2004, 41(4), 293-304.
83. Kim, C. W.; Son, K. N.; Choi, S. Y.; Kim, J. Human lactoferrin upregulates expression of KDR/Flk-1 and stimulates VEGF-Amediated endothelial cell proliferation and migration. FEBS Lett., 2006, 580(18), 4332-4336.
84. Westermarck, J.; Kahari, V. M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J., 1999, 13(8), 781-792.
85. Tsuda, H.; Sekine, K.; Takasuka, N.; Toriyama-Baba, H.; Iigo, M. Prevention of colon carcinogenesis and carcinoma metastasis by orally administered bovine lactoferrin in animals. Biofactors, 2000, 12(1-4), 83-88.
86. Kuhara, T.; Iigo, M.; Itoh, T.; Ushida, Y.; Sekine, K.; Terada, N.; Okamura, H.; Tsuda, H. Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium. Nutr. Cancer, 2000, 38(2), 192-199.
87. Iigo, M.; Shimamura, M.; Matsuda, E.; Fujita, K.; Nomoto, H.; Satoh, J.; Kojima, S.; Alexander, D. B.; Moore, M. A.; Tsuda, H. Orally administered bovine lactoferrin induces caspase-1 and interleukin-18 in the mouse intestinal mucosa: a possible explanation for inhibition of carcinogenesis and metastasis. Cytokine, 2004, 25(1), 36-44.
88. Iigo, M.; Kuhara, T.; Ushida, Y.; Sekine, K.; Moore, M. A.; Tsuda, H. Inhibitory effects of bovine lactoferrin on colon carcinoma 26 lung metastasis in mice. Clin. Exp. Metastasis, 1999, 17(1), 35-40.
89. Bezault, J.; Bhimani, R.; Wiprovnick, J.; Furmanski, P. Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. Cancer Res., 1994, 54(9), 2310-2312.
90. Iigo, M.; Alexander, D. B.; Long, N.; Xu, J.; Fukamachi, K.; Futakuchi, M.; Takase, M.; Tsuda, H. Anticarcinogenesis pathways activated by bovine lactoferrin in the murine small intestine. Biochimie, 2009, 91(1), 86-101.
91. Wu, M.; Li, X.; Li, X.; Li, G. Signaling Transduction Network Mediated by Tumor Suppressor/Susceptibility Genes in NPC. Curr. Genomics, 2009, 10(4), 216-222.
92. Deng, M.; Zhang, W.; Tang, H.; Ye, Q.; Liao, Q.; Zhou, Y.; Wu, M.; Xiong, W.; Zheng, Y.; Guo, X.; Qin, Z.; He, W.; Zhou, M.; Xiang, J.; Li, X.; Ma, J.; Li, G. Lactotransferrin acts as a tumor suppressor in nasopharyngeal carcinoma by repressing AKT through multiple mechanisms. Oncogene, 2012,[Epub ahead of print]
93. Sorlie, T.; Perou, C. M.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M. B.; van de Rijn, M.; Jeffrey, S. S.; Thorsen, T.; Quist, H.; Matese, J. C.; Brown, P. O.; Botstein, D.; Lonning, P. E.; Borresen-Dale, A. L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U S A, 2001, 98(19), 10869-10874.
94. van T, V. L.; Dai, H.; van de Vijver, M. J.; He, Y. D.; Hart, A. A.; Mao, M.; Peterse, H. L.; van der Kooy, K.; Marton, M. J.; Witteveen, A. T.; Schreiber, G. J.; Kerkhoven, R. M.; Roberts, C.; Linsley, P. S.; Bernards, R.; Friend, S. H. Gene expression profiling predicts clinical outcome of breast cancer. Nature, 2002, 415(6871), 530-536.
95. Ha, N. H.; Nair, V. S.; Reddy, D. N.; Mudvari, P.; Ohshiro, K.; Ghanta, K. S.; Pakala, S. B.; Li, D. Q.; Costa, L.; Lipton, A.; Badwe, R. A.; Fuqua, S.; Wallon, M.; Prendergast, G. C.; Kumar, R. Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. Cancer Res., 2011, 71(23), 7259-7269.
96. Eliassen, L. T.; Berge, G.; Sveinbjornsson, B.; Svendsen, J. S.; Vorland, L. H.; Rekdal, O. Evidence for a direct antitumor mechanism of action of bovine lactoferricin. Anticancer Res., 2002, 22(5), 2703-2710.
97. Berge, G.; Eliassen, L. T.; Camilio, K. A.; Bartnes, K.; Sveinbjornsson, B.; Rekdal, O. Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide. Cancer Immunol. Immunother., 2010, 59(8), 1285-1294.
98. Wolf, J. S.; Li, D.; Taylor, R. J.; O'Malley, B. J. Lactoferrin inhibits growth of malignant tumors of the head and neck. ORL J. Otorhinolaryngol. Relat. Spec., 2003, 65(5), 245-249.
99. Zheng, Y.; Zhang, W.; Ye, Q.; Zhou, Y.; Xiong, W.; He, W.; Deng, M.; Zhou, M.; Guo, X.; Chen, P.; Fan, S.; Liu, X.; Wang, Z.; Li, X.; Ma, J.; Li, G. Inhibition of Epstein-Barr virus infection by lactoferrin. J. Innate Immun., 2012, 4(4), 387-398.
100. Sakai, T.; Banno, Y.; Kato, Y.; Nozawa, Y.; Kawaguchi, M. Pepsin-digested bovine lactoferrin induces apoptotic cell death with JNK/SAPK activation in oral cancer cells. J. Pharmacol. Sci., 2005, 98(1), 41-48.
101. Chandra, M. K.; Devaraj, H.; Prathiba, D.; Hara, Y.; Nagini, S. Antiproliferative and apoptosis inducing effect of lactoferrin and black tea polyphenol combination on hamster buccal pouch carcinogenesis. Biochim. Biophys. Acta, 2006, 1760(10), 1536-1544.
102. Mohan, K. V.; Letchoumy, P. V.; Hara, Y.; Nagini, S. Combination chemoprevention of hamster buccal pouch carcinogenesis by bovine milk lactoferrin and black tea polyphenols. Cancer Invest., 2008, 26(2), 193-201.
103. Letchoumy, P. V.; Mohan, K. V.; Stegeman, J. J.; Gelboin, H. V.; Hara, Y.; Nagini, S. In vitro antioxidative potential of lactoferrin and black tea polyphenols and protective effects in vivo on carcinogen activation, DNA damage, proliferation, invasion, and angiogenesis during experimental oral carcinogenesis. Oncol. Res., 2008, 17(5), 193-203.
104. Tanaka, T.; Kawabata, K.; Kohno, H.; Honjo, S.; Murakami, M.; Ota, T.; Tsuda, H. Chemopreventive effect of bovine lactoferrin on 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male F344 rats. Jpn. J. Cancer Res., 2000, 91(1), 25-33.
105. Furlong, S. J.; Mader, J. S.; Hoskin, D. W. Lactoferricin-induced apoptosis in estrogen-nonresponsive MDA-MB-435 breast cancer cells is enhanced by C6 ceramide or tamoxifen. Oncol. Rep., 2006, 15(5), 1385-1390.
106. Wang, J.; Li, Q.; Li, K.; Ou, Y.; Han, Z.; Gao, D.; Li, J. Effects of adenovirus vectors mediated human lactoferrin cDNA on mice bearing EMT6 breast carcinoma. Pharmazie, 2011, 66(9), 704-709.
107. Li, D.; Sakashita, S.; Morishita, Y.; Kano, J.; Shiba, A.; Sato, T.; Noguchi, M. Binding of lactoferrin to IGBP1 triggers apoptosis in a lung adenocarcinoma cell line. Anticancer Res., 2011, 31(2), 529-534.
108. Xu, X. X.; Jiang, H. R.; Li, H. B.; Zhang, T. N.; Zhou, Q.; Liu, N. Apoptosis of stomach cancer cell SGC-7901 and regulation of Akt signaling way induced by bovine lactoferrin. J. Dairy Sci., 2010, 93(6), 2344-2350.
109. Mader, J. S.; Richardson, A.; Salsman, J.; Top, D.; de Antueno, R.; Duncan, R.; Hoskin, D. W. Bovine lactoferricin causes apoptosis in Jurkat T-leukemia cells by sequential permeabilization of the cell membrane and targeting of mitochondria. Exp. Cell. Res., 2007, 313(12), 2634-2650.
110. Tamano, S.; Sekine, K.; Takase, M.; Yamauchi, K.; Iigo, M.; Tsuda, H. Lack of chronic oral toxicity of chemopreventive bovine lactoferrin in F344/DuCrj rats. Asian Pac. J. Cancer Prev., 2008, 9(2), 313-316.
111. Kang, J. H.; Lee, M. K.; Kim, K. L.; Hahm, K. S. Structurebiological activity relationships of 11-residue highly basic peptide segment of bovine lactoferrin. Int. J. Pept. Protein Res., 1996, 48(4), 357-363.
112. Gibbons, J. A.; Kanwar, R. K.; Kanwar, J. R. Lactoferrin and cancer in different cancer models. Front. Biosci. (Schol Ed), 2011, 3, 1080-1088.
113. Spadaro, M.; Caorsi, C.; Ceruti, P.; Varadhachary, A.; Forni, G.; Pericle, F.; Giovarelli, M. Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells. FASEB J., 2008, 22(8), 2747-2757.
114. Thomas, A.; Hassan, R. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol., 2012, 13(7), e301-e310.
115. Tsuda, H.; Kozu, T.; Iinuma, G.; Ohashi, Y.; Saito, Y.; Saito, D.; Akasu, T.; Alexander, D. B.; Futakuchi, M.; Fukamachi, K.; Xu, J.; Kakizoe, T.; Iigo, M. Cancer prevention by bovine lactoferrin: from animal studies to human trial. Biometals, 2010, 23(3), 399-409.
116. Siebert, P. D.; Huang, B. C. Identification of an alternative form of human lactoferrin mRNA that is expressed differentially in normal tissues and tumor-derived cell lines. Proc. Natl. Acad. Sci. U S A, 1997, 94(6), 2198-2203.
117. Vogel, H. J. Lactoferrin, a bird's eye view. Biochem. Cell. Biol., 2012, 90, (3), 233-244.
118. Onishi, H. Lactoferrin delivery systems: approaches for its more effective use. Expert Opin. Drug Deliv., 2011, 8(11), 1469-1479.
119. Wei, M.; Xu, Y.; Zou, Q.; Tu, L.; Tang, C.; Xu, T.; Deng, L.; Wu, C. Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin. Eur. J. Pharm. Sci., 2012, 46(3), 131-141.